arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Pacira BioSciences, Inc.

PCRX
$36.45 ▲ +0.03 (+0.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
55
Health
Fair
Neutral
auto_awesome

Analytical Summary

Pacira BioSciences, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.4B
Dividend Yield —
Revenue Growth 6.2% ↗
Op. Margin 2.2% ↘
ROIC 0.8% ↗
FCF / Share $1.42 ↗
Trailing P/E 303.8x
Price / Book 2.2x
FCF Yield 3.9%
Debt / Equity 0.54
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$192.40M
↑ +6.2% —
Net Income Profit after all expenses
$4.65M
↑ +59.6% —
Operating Margin Operating profit as % of sales
2.2%
↓ -43.0% 36th
FCF / Share Free cash flow per share
$1.42
↑ +150.7% —
Long-Term Debt Long-term obligations
$363.12M
↓ -1.2% —

Health Breakdown

Profitability ↓
50
Returns ↓
46
Financial Health →
52
Cash Quality ↑
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters